Wednesday 6-18-2014 Amgen Inc (AMGN) $AMGN opened at 116.44

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
Wednesday 6-18-2014 Amgen Inc (AMGN) $AMGN opened at 116.44 hitting the high price of 117.56 and a day low of 115.50 with a total volume of 2,549,136. AMGN had a previous close of 116.17 and has been seeing an average volume of 2,418,345.

Overall Average: 8% Buy

Recent stock forum discussions about AMGN http://investorshangout.com/search?q=AMGN&...mp;yt0=Go!

Final Glance: Biotechnology companies
AP - 2 hrs 45 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)

Amgen Rises 1.14% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Jun 18, 4:13PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $115.50 to a high of $117.56. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $116.91 on volume of 2.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)

Look for Shares of Amgen to Potentially Pullback after Yesterday's 1.14% Rise
Comtex SmarTrend(R) - Wed Jun 18, 4:13PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $115.50 to a high of $117.56. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $116.91 on volume of 2.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)

Midday Glance: Biotechnology companies
AP - Wed Jun 18, 1:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.: (full story)

Early Glance: Biotechnology companies
AP - Wed Jun 18, 10:36AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)

Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue
M2 - Wed Jun 18, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dj8ssn/vital_signs) has announced the addition of the "Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue" report to their offering. This issue of Vital Signs, released on February 28, 2014, discusses three M&A transactions this month by Nestle, Myriad Genetics, and Fludigm' and what these deals mean for the industry. Additionally, Illumina's first stab at personalized medicine through a partnership with Amgen is explored. For more information visit http://www.researchandmarkets.com/research/dj...ital_signs About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. (full story)

3 Undervalued Amgen Growth Opportunities to Watch
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Jun 16, 4:30PM CDT
Amgen hasn't put as many eggs into the megablockbuster basket as Merck or Bristol-Myers Squibb , nor has it sought to utterly dominate a therapeutic area the way Biogen Idec may dominate MS. What Amgen does offer, though, is a deep pipeline... (full story)

Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer
PR Newswire - Mon Jun 16, 3:03PM CDT
Amgen (NASDAQ:AMGN) announced today that it will collaborate with the National Cancer Institute (NCI), part of the National Institutes of Health, and other public and private sector partners on the Lung Master Protocol (Lung-MAP), a groundbreaking new clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles. Lung-MAP is the first trial of its kind to study a large number of rare lung cancer subsets under one trial protocol. (full story)

Groundbreaking Collaborative Clinical Trial Launched
PR Newswire - Mon Jun 16, 8:00AM CDT
A unique public-private collaboration among the National Cancer Institute (NCI), part of the National Institutes of Health, SWOG Cancer Research, Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca's global biologics R&D arm, MedImmune), and Foundation Medicine today announced the initiation of the Lung Cancer Master Protocol (Lung-MAP) trial. (full story)

Is Gene Therapy Medicine's Next Big Thing?
Todd Campbell, The Motley Fool - Motley Fool - Sat Jun 14, 12:05PM CDT
Bluebird Bio is a small company with big ideas. The clinical stage biotechnology company is researching novel treatments that seek to insert missing genes into patient stem cells. The science behind  Bluebird's approach is so compelling that ... (full story)

The Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and Amgen
PR Newswire - Fri Jun 13, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the China Mobile Limited (NYSE:CHL-Free Report), China Petroleum and Chemical Corp. (NYSE:SNP-Free Report), Trina Solar Limited (NYSE:TSL-Free Report), AstraZeneca (NYSE:AZN-Free Report) andAmgen (Nasdaq:AMGN-Free Report). (full story)

Is Amgen's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jun 12, 4:30PM CDT
Amgen is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares. Big drug companies such as Amgen, AbbVie , and Johnson... (full story)

Amgen-AstraZeneca Psoriatic Arthritis Drug Shows Improvement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 4:10PM CDT
AstraZeneca (AZN) and partner Amgen (AMGN) announced that data from a phase II study evaluating the use of brodalumab in patients suffering from psoriatic arthritis was published in The New England Journal of Medicine. (full story)

Amgen Inc. (AMGN) Stock Research Links

AMGN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 77

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
CustomerInsights.AI Fast 500 Nod Tests Its AI Model

Updated Category News Views 44

Pharma’s analytics mess is exactly where CustomerInsights.AI has chosen to make its stand. The Scottsdale company’s inclusion in Deloitte’s 2026 Technology Fast 500, announced November 19, is a useful signal that its pitch is finding buyers: life-sciences businesses want AI to do actual commercial work, not sit in a lab demo collecting dust. Still, a Fast 500 badge...

Continue Reading
Zoomlion’s Australian Service Push Looks Built to Last

Updated Category News Views 113

Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...

Continue Reading
ATRenew's Q3 Profit Jump Meets a Cash Balance Test

Updated Category News Views 105

Used phones do not make for glamorous investing, but this quarter has some real muscle behind it. ATRenew turned a 25.3% revenue gain into a 57.9% jump in operating income for the three months ended September 30, and that is the sort of operating leverage I want to see before getting carried away with a circular-economy story. Margins Finally Move in the Right Direction...

Continue Reading
Teciem’s New CFO Puts Financial Discipline Behind Growth

Updated Category News Views 87

A finance chief moving continents is not decorative corporate wallpaper. Teciem’s decision to appoint Jesús Rueda Molins as chief financial officer says the company wants its next growth chapter run with more than product ambition and executive slogans. It wants somebody holding the purse strings who already knows the machinery, the customers and the people making the...

Continue Reading
Mile High Labs Moves CBD Isolate Into FDA DMF Pathway

Updated Category News Views 76

A Quiet Filing With Real Commercial Weight Cannabis headlines usually arrive wearing a clown suit; this one showed up with paperwork. Mile High Labs says it filed Type II Drug Master File No. 044151 with the U.S. Food and Drug Administration for a 98% CBD isolate on October 2, 2026. That is not a product approval, not permission to market a CBD drug, and certainly not a...

Continue Reading
Royce Global Trust's Discount Is Still the Whole Debate

Updated Category News Views 67

A $3.03 gap is staring investors right in the face. As of October 31, 2026, Royce Global Trust carried a net asset value of $17.51 per share while the market price sat at $14.48. That works out to roughly a 17.3% discount to NAV, and with a closed-end fund, that discount is not some footnote shoved under the table. It is a major part of the return story, good or bad. The...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 144

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 122

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Clickstop's Urbana Expansion Bets on Durable Demand

Updated Category News Views 63

A patch of turned Iowa dirt can say plenty about a company’s nerve. Clickstop broke ground in Urbana on Nov. 19, 2026, for a 43,000-square-foot building, and the message is pretty plain: management believes its recent growth has legs. For a privately held, employee-owned operator serving trucking, construction, lifting and rigging, that is not a casual decision....

Continue Reading

Top 5 Most Recently Viewed Articles

Nokia Corporation Reports Managerial Transaction Details

Updated Category News Views 170

Nokia Corporation’s Managerial Transaction Insights Nokia Corporation has been making headlines recently as it showcases the ongoing engagement of its management in company affairs. An important transaction notification concerning Nishant Batra, a senior manager at Nokia, has been released, highlighting the movement of shares within the company. Transaction Overview...

Continue Reading
RBI Urges Banks to Limit Short Selling as Rupee Dips

Updated Category News Views 121

RBI's Call to Support the Rupee Amidst Market Challenges The Reserve Bank of India (RBI) has recently taken proactive measures to address the vulnerabilities of the Indian rupee, which has been hovering close to unprecedented low levels. This action follows a period in which market fluctuations have raised concerns among financial circles, particularly regarding the...

Continue Reading
Workhorse Group's E-GEN Platform Achieves Major Milestone

Updated Category News Views 260

Revolutionizing Commercial Transportation with E-GEN Milestone Workhorse Group Inc., renowned for its pioneering electric vehicle solutions, achieved an incredible feat with its E-GEN vehicles recently surpassing a remarkable 10 million cumulative miles. This significant milestone not only validates the platform’s durability but also showcases its reliability in...

Continue Reading
Investors Urged to Act Ahead of Starbucks Class Action Deadline

Updated Category News Views 231

Important Deadline for Starbucks Corporation Investors In light of recent developments, investors who purchased securities of Starbucks Corporation (NASDAQ: SBUX) are being encouraged to take action before an important deadline. Rosen Law Firm, a well-respected global investor rights law firm, has issued reminders for these investors. They are informing those who bought...

Continue Reading
Effective Strategies to Enhance Your Credit Before Holidays

Updated Category News Views 78

Essential Strategies for Boosting Your Credit Score TomoCredit, a dedicated platform aiding immigrants and underserved communities in accessing crucial credit without relying on credit scores, has developed a practical 5-week plan to help consumers enhance their credit before the holiday shopping frenzy. This guide aims to empower individuals to take control of their...

Continue Reading